Search results for "CoV"

showing 10 items of 9749 documents

Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial.

1995

Interferon alpha-2a (IFN-alpha) and folinic acid (FA) have been shown to modulate the cytotoxic effects of 5-fluorouracil (5-FU) in the treatment of cancer. A phase II study was initiated to evaluate the effect of a combination of 5-FU/FA/IFN-alpha in patients with advanced pancreatic cancer. Sixty previously untreated patients with advanced adenocarcinoma of the pancreas were treated with 500 mg m-2 FU via an intravenous bolus 1 h after the initiation of a 2 h infusion of 500 mg m-2 FA. Before starting the FA infusion, 6 million units (MU) of IFN-alpha was administered subcutaneously. The treatment was repeated once a week. Of 57 evaluable patients, eight (14%) had a partial response (PR),…

AdultMaleCancer Researchmedicine.medical_specialtyPancreatic diseasemedicine.medical_treatmentLeucovorinAlpha interferonAdenocarcinomaInterferon alpha-2GastroenterologyFolinic acidInternal medicinePancreatic cancerAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInterferon alfaAgedChemotherapybusiness.industryInterferon-alphaMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryPancreatic NeoplasmsOncologyFluorouracilFemaleFluorouracilbusinessProgressive diseasemedicine.drugResearch ArticleBritish Journal of Cancer
researchProduct

Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study

2005

The aims of this multicentre, randomised phase III trial were to evaluate: (1) the role of levamisol (LEV); and (2) the role of folinic acid (FA), added to 5-fluorouracil (5FU) in the adjuvant treatment of colorectal cancer. Patients with histologically proven, radically resected stage II or III colon or rectal cancer were eligible. The study had a 2x2 factorial design with four treatment arms: (a) 5FU alone, (b) 5FU+LEV, (c) 5FU+FA, (d) 5FU+LEV+FA, and two planned comparisons, testing the role of LEV and of FA, respectively. From March 1991, to September 1998, 1327 patients were randomised. None of the two comparisons resulted in a significant disease-free (DFS) or overall (OAS) survival a…

AdultMaleCancer Researchmedicine.medical_specialtyRandomization5-fluorouracil modulation; adjuvant chemotherapy; colorectal cancermedicine.drug_classColorectal cancerLeucovorincolorectal cancerAntimetaboliteGastroenterologyDisease-Free SurvivalFolinic acidRECTAL CANCER5-fluorouracil modulationCOLONInternal medicineClinical StudiesAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisHumansAgedbusiness.industryHazard ratioMiddle Agedmedicine.diseaseSurgeryadjuvant chemotherapyTreatment OutcomeLevamisoleOncologyChemotherapy AdjuvantFluorouracilVomitingFemaleFluorouracilmedicine.symptomColorectal Neoplasmsbusinessmedicine.drugBritish Journal of Cancer
researchProduct

Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Del…

2005

Purpose We performed this phase III study to compare the irinotecan, leucovorin (LV), and fluorouracil (FU) regimen (FOLFIRI) versus the oxaliplatin, LV, and FU regimen (FOLFOX4) in previously untreated patients with advanced colorectal cancer. Patients and Methods A total of 360 chemotherapy-naive patients were randomly assigned to receive, every 2 weeks, either arm A (FOLFIRI: irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2 [LV5FU2]) or arm B (FOLFOX4: oxaliplatin 85 mg/m2 on day 1 with LV5FU2 regi…

AdultMaleCancer Researchmedicine.medical_specialtyRandomizationOrganoplatinum CompoundsColorectal cancerfolinic acidatropineplatinum complexLeucovorinGastroenterologylaw.inventionRandomized controlled trialFolfox protocollawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions Intravenousirinotecanantineoplastic agentAgedbusiness.industryoxaliplatinMiddle Agedmedicine.diseaseSurvival AnalysisOxaliplatinSurgeryIrinotecanRegimenTreatment OutcomeOncologyFluorouracildrug derivativeDisease ProgressionFOLFIRICamptothecinFemaleFluorouracilIFL protocolColorectal Neoplasmsbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in…

2005

An open-label randomised comparison of efficacy and tolerability of irinotecan plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) (ILF) with etoposide plus 5-FU/LV (ELF) in patients with untreated metastatic or locally advanced gastric cancer. One cycle of ILF comprised six once-weekly infusions of irinotecan 80 mg m(-2), LV 500 mg m(-2), 24-h 5-FU 2000 mg m(-2), and ELF comprised three once-daily doses of etoposide 120 mg m(-2), LV 300 mg m(-2), 5-FU 500 mg m(-2). In all, 56 patients received ILF and 58 ELF. Median age was 62 years, Karnofsky performance 90%, and disease status was comparable for both arms. The objective clinical response rates after 14 weeks treatment (primary end p…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classLeucovorinPhases of clinical researchNeutropeniaAdenocarcinomaIrinotecanAntimetaboliteGastroenterologygastricStomach NeoplasmsInternal medicineClinical StudiesAntineoplastic Combined Chemotherapy ProtocolsMedicineHumans5-fluorouracilStomach cancerEtoposidePeritoneal NeoplasmsAgedEtoposideNeoplasm StagingLevoleucovorinbusiness.industryMiddle Agedmedicine.diseaseSurvival AnalysisSurgerymetastaticIrinotecanELFTreatment OutcomeOncologyTolerabilityFluorouracilCamptothecinFemaleEsophagogastric JunctionFluorouracilbusinessILFmedicine.drugBritish Journal of Cancer
researchProduct

Weekly Levofolinic Acid and 5-Fluorouracil Plus Hydroxyurea in Metastatic Gastrointestinal Adenocarcinomas

1994

There were 42 patients with advanced gastrointestinal carcinomas (GA) enrolled in the study. In the Phase I part of the study we identified the MTD of 5-fluorouracil (5FU) in combination with levofolinic acid 100 mg/m2 per week intravenously plus hydroxyurea 1 g/m2 per week given by mouth in 3 refracted doses starting 6 hours after 5FU was administered. This treatment was given weekly for 6 consecutive weeks followed by a 15-day rest period. We were not able to increase 5FU weekly dosage above 700 mg/m2 due to the occurrence of grade 3-4 gastrointestinal toxicity. Thus 5FU was employed at 600 mg/m2 per week for the Phase II part of the study. Among 20 evaluable patients with measurable meta…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentLeucovorinRectumAdenocarcinomaGastroenterologyAntimetaboliteDrug Administration ScheduleHydroxycarbamideInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansHydroxyureaAgedGastrointestinal NeoplasmsChemotherapybusiness.industryMiddle AgedSurvival AnalysisSurgeryRegimenmedicine.anatomical_structureOncologyFluorouracilToxicityVomitingFemaleFluorouracilmedicine.symptombusinessmedicine.drugAmerican Journal of Clinical Oncology
researchProduct

Anatomical Correlate of Impaired Covert Visual Attentional Processes in Patients with Cerebellar Lesions

2010

In the past years, claims of cognitive and attentional function of the cerebellum have first been raised but were later refuted. One reason for this controversy might be that attentional deficits only occur when specific cerebellar structures are affected. To further elucidate this matter and to determine which cerebellar regions might be involved in deficits of covert visual attention, we used new brain imaging tools of lesion mapping that allow a direct comparison with control patients. A total of 26 patients with unilateral right-sided cerebellar infarcts were tested on a covert visual attention task. Eight (31%) patients showed markedly slowed responses, especially in trials in which an…

AdultMaleCerebellumgenetic structuresCerebellar lesionsNeuroimagingCerebellumReaction TimemedicineHumansVisual attentionAttentionIn patientAgedAged 80 and overGeneral NeuroscienceCognitionArticlesMiddle Agedmedicine.anatomical_structureOculomotor controlCovertVisual PerceptionFemalePsychologyNeurosciencePhotic StimulationPsychomotor PerformanceCognitive psychologyThe Journal of Neuroscience
researchProduct

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera

2021

Vaccine protects against B1.1.7 variant The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B1.1.7 (VOC 202012/01) variant that emerged in late 2020 in the United Kingdom has many changes in the spike protein gene. Three of these are associated with enhanced infectivity and transmissibility, and there are concerns that B.1.1.7 might compromise the effectiveness of the vaccine. Muik et al. compared the neutralization efficacy of sera from 40 subjects immunized with the BioNTech-Pfizer mRNA vaccine BNT162b2 against a pseudovirus bearing the Wuhan reference strain or the lineage B.1.1.7 spike protein (see the Perspective by Altmann et al.). Serum was derived from 40 subjects in tw…

AdultMaleChinaCOVID-19 VaccinesLineage (genetic)Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Antibodies ViralNeutralizationYoung AdultNeutralization TestsReportHumansBNT162 VaccineAgedchemistry.chemical_classificationVaccinesMessenger RNAMultidisciplinarybiologySARS-CoV-2COVID-19MicrobioMiddle AgedAntibodies NeutralizingVirologyUnited KingdomAmino acidTiterchemistrySpike Glycoprotein Coronavirusbiology.proteinMedicineFemaleAntibodyReportsScience
researchProduct

Comparison of clinical characteristics between coronavirus disease 2019 pneumonia and community-acquired pneumonia

2020

Coronavirus disease 2019 (COVID-19) has high morbidity and mortality, and spreads rapidly in the community to result in a large number of infection cases. This study aimed to compare clinical features in adult patients with coronavirus disease 2019 (COVID-19) pneumonia to those in adult patients with community-acquired pneumonia (CAP).Clinical presentations, laboratory findings, imaging features, complications, treatment and outcomes were compared between patients with COVID-19 pneumonia and patients with CAP. The study group of patients with COVID-19 pneumonia consisted of 120 patients. One hundred and thirty-four patients with CAP were enrolled for comparison.Patients with COVID-19 pneumo…

AdultMaleChinamedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Pneumonia Viral030204 cardiovascular system & hematologySeverity of Illness IndexBetacoronavirus03 medical and health sciences0302 clinical medicineCommunity-acquired pneumoniaInternal medicineSeverity of illnessPandemicmedicineHumans030212 general & internal medicinePandemicsAgedRetrospective StudiesbiologySARS-CoV-2business.industryCase-control studyCOVID-19Retrospective cohort studyGeneral MedicineMiddle AgedPrognosisbiology.organism_classificationmedicine.diseaseCommunity-Acquired InfectionsPneumoniaCase-Control StudiesFemaleCoronavirus InfectionsbusinessBetacoronavirusCurrent Medical Research and Opinion
researchProduct

Comparison of physical activity levels in Spanish adults with chronic conditions before and during COVID-19 quarantine

2020

Abstract Background This is the first study analyzing levels of physical activity in a sample of quarantined adults with chronic conditions. The aim of this study was to compare moderate- and vigorous-intensity physical activity levels in Spanish adults with chronic conditions before and during coronavirus disease 2019 (COVID-19) quarantine. Methods A cross-sectional online survey was administered during the COVID-19 quarantine in Spain. A total of 163 participants with chronic conditions (113 females and 47 males; age range 18–64 years) completed the survey. A total of 26 chronic conditions were included. Participants self-reported average minutes/day of moderate and vigorous physical acti…

AdultMaleChronic conditionAdolescentCoronavirus disease 2019 (COVID-19)Cross-sectional studyPhysical activityOriginal Manuscriptlaw.inventionYoung Adult03 medical and health sciences0302 clinical medicinelawQuarantineadultsmedicineHumansChronic skin diseaseAcademicSubjects/MED00860AcademicSubjects/SOC01210030212 general & internal medicineYoung adultExerciseAgedAsthmaPhysical activitySARS-CoV-2business.industryPublic Health Environmental and Occupational HealthCOVID-19Middle Agedchronic conditionsmedicine.diseaseCross-Sectional StudiesSpainChronic DiseaseQuarantineFemaleCorrigendumbusinessAcademicSubjects/SOC02610030217 neurology & neurosurgeryDemography
researchProduct

Development and validation of a reliable method for studying the distribution pattern for opiates metabolites in brain

2012

Abstract Brain distribution pattern of “street” heroin metabolites (morphine and codeine) was investigated in two fatalities due to “acute narcotism”. A suitable sample pretreatment prior to solid-phase-extraction was developed to achieve a good recovery of the analytes and to eliminate the interfering species. After derivatization with MSTFA, samples were analyzed by GC/MS. Specificity, accuracy, precision and linearity of the method were evaluated; LOD and LOQ were, respectively, 10 ng/25 ng for morphine and 5 ng/10 ng for codeine. This method was applied to the analysis of six brain areas (hippocampus, frontal lobe, occipital lobe, nuclei, bulb and pons) coming from two cases of heroin-r…

AdultMaleClinical BiochemistryAnalytical chemistryPharmaceutical ScienceHippocampusGas Chromatography-Mass SpectrometryAnalytical ChemistryHeroinchemistry.chemical_compoundSettore MED/43 - Medicina LegaleLimit of DetectionDrug DiscoverymedicineHumansTissue DistributionDerivatizationSpectroscopyHeroin; Morphine; Codeine; Post-mortem brain specimenChromatographyMolecular StructureMorphineCodeineHeroin DependenceIllicit DrugsCodeineBrainReproducibility of ResultsPonsHeroinSubstance Abuse DetectionchemistryFrontal lobeMorphinePost-mortem brain specimenDrug OverdoseOccipital lobemedicine.drug
researchProduct